ARID1A and lung carcinoma: Since EGFR is infrequently mutated in treatment-naïve CRC (0.5%)25, we also performed this analysis in the 29,757 FoundationCORE® lung cancer samples, a tumor type where EGFR and ARID1A mutations are more frequently detected at baseline39.